Wednesday November 28

West Coast Day 1

The Big Picture

Dr Richard Pan
08:10

Keynote Opening Address: The impact of vaccine legislation on public health in California

Panel discussion
08:35

Addressing the epidemic of misinformation

  • What are the key drivers of hesitancy to vaccinate?
    • Complacency, convenience and confidence
  • What works in tackling misinformation and building trust?
    • E.g. what steps are being taken to counteract sophisticated social media campaigns of parent groups?
  • What responsibility do public health and education authorities have and how can companies get involved?
Dr Janelle Ayres
09:20

Novel approaches to fighting infectious diseases and the increasing global threat of Anti-Microbial Resistance

  • What are the limitations in the approaches used to fight infections currently?
  • What new approaches should we be practicing that benefits us in the long-term?
Panel discussion
09:45

The evolution of antibody therapy for cancer

  • Progress in the development of antibody drug conjugates,bispecific antibodies, and fusion protein/antibodies
  • Novel approaches in antibody therapy- who is leading the next generation of antibody development?
  • What have been the most successful and least successful antibody therapies? Why?
  • How do we decide what level of toxicity is acceptable? Does this vary across indications?
Dr Hanspeter Gerber, CSO, 3 T Biosciences
10:30

Morning Networking Break & Poster Session

Respiratory Diseases

Cancer Vaccine Development

Trial design and analysis

Clinical Trials
11:35

Designing innovative cohort adaptive sequential trials in oncology and other therapeutic areas

  • How can innovative trial design help speed the development process and make it more accurate?
  • Using one trial to address and identify the benefitting patient subpopulation
Vaccine Development
12:05

Efficacy, Safety and immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

  • Placebo-controlled Phase 3 efficacy results of QIV seasonal VLPs in healthy adults
  • Review of safety profile
  • Comparison of humoral and cell-mediated immune responses induced by VLPs in stratified age groups (18-49 and 50-64 years of age)
Clinical Trials
12:05

Lung- MAP: using state-of-the-art genomic profiling to match patients to the most appropriate clinical trial

  • Overview of umbrella trials
  • What are the advantages of using this type trial design?
    • Reduction of cost, patient access, accelerated development
  • Efforts to create an immunotherapy clinical trial platform within the trial design to allow for running of multiple studies at the same time.
Immuno-Oncology
12:20

Tools to identify, predict and prioritize vaccine candidates

  • Clinical challenges in cancer immunotherapy.
  • Personalized cancer vaccines have the potential to enhance the efficacy of checkpoint inhibitors but predicting them from somatic mutations is a formidable challenge
  • Overview of approach to build better vaccine cocktails.
  • Understand integrated genomics and cell-based solutions in the cancer immunotherapy space, including application of whole transcriptome analysis to characterize the tumor microenvironment and biomarker discovery approaches to predict patient response.
Immuno-Oncology
12:50

Immunomic is addressing the challenges of viral targets in cancer

  • Immunomic is addressing the challenges in I-O by applying our proven UNITE technology platform
  • LAMP-based nucleic acid immunotherapies have the potential to broaden the current use of cancer immunotherapy by complementing approved and investigational approaches.
  • LAMP-based nucleic acid immunotherapy has potential as cancer immunotherapy in two general ways:
    • Activation of the immune system against highly immunogenic tumor types, potentially amplifying the response seen with checkpoint inhibitors
    • Creation of a new, robust immune response to tumor types that don’t otherwise provoke an immune reaction, by reconfiguring a critical component of our immune system
  • Several discovery stage programs for virally driven cancers including MCC, NPC/Gastric and HCC. INDs to be filed for these programs in 2019.
1:20

Networking Lunch & Poster Session

Dr Peter Hotez
2:00

Lunchtime presentation & book signing: “Vaccines did not cause Rachel’s Autism”

Vaccine Development
2:50

A live attenuated pertussis vaccine to prevent disease, colonization and transmission

  • Why we need aB. pertussisvaccine that induces potentmucosal immunity
  • Relationship between colonizing nasopharyngeal infection and disease
  • Mechanism of action for a live attenuated intranasal vaccine
  • Non-human primate challenge model data
  • Clinical study results
Immuno-Oncology
2:50

Next generation platform for the development of personalized synthetic cancer vaccines

  • Development of vaccine platform from concept to delivery
    • Bioinformatic immunogen design, use of long peptides and heat shock proteins
  • Challenges of working with peptides
  • Selecting the correct mutations in each patient
  • Parallel approach to selecting neoantigens represented by abnormal post-translational modifications
  • Potential for combination therapy
Vaccine Development
3:20

Pertussis and Pertussis vaccines; mistakes made during a 112 year odyssey and what some of those mistakes bode for the future

  • During the 20th century, B. pertussis was extensively studied in animal model systems and many “toxins” and protective antigens were described.
  • DTaP vaccines were developed and put into general use in the USA in 1997.
  • During the last 13 years, major pertussis epidemics have occurred in the USA due to deficiencies in DTaP vaccines.
  • Two of the deficiencies are the small number of antigens and the type of cellular immune response.
  • The small number of antigens leads to linked-epitope suppression.
  • Because of linked-epitope suppression, all children who were primed by DTaP vaccines will be more susceptible to pertussis throughout their lifetimes.
Immuno-Oncology
3:20

Overcoming tumor immune suppression using a novel retroviral replicating vector

  • Pre-clinical data: observations to support immune mediated mechanism of action
  • Phase 1 data in recurrent high-grade glioma: durable complete responses seen in dose escalation studies
  • Clinical Development: Food and Drug Administration Breakthrough Therapy Designation, European Medicines Agency’s PRIME designation and Phase 3 trial in recurrent glioblastoma and anaplastic astrocytoma
  • Updates in studies for solid tumors

Mosquito-Borne Diseases

T-cell therapies

Infectious diseases

Vaccine Development
3:50

Updates in the clinical development of a chikungunya vaccine

  • Trends in chikungunya epidemiology
  • VLP vaccine technology
  • Updates in phase 2 clinical trials
4:20

Afternoon Networking Break

Vaccine Development
5:20

Panel: Is there a future for arbovirus vaccines?

  • What is the current landscape for dengue, zika and other arbovirus vaccines?
  • Which other arboviruses should be prioritized for vaccine development or for improvements of the existing vaccine(s)?
  • What might emerging arboviruses look like and what improvements are needed in current vaccines?
  • Finding a better way to evaluate these vaccines before going into phase 3 trials.
  • Using human protection models to discover the keys to eliciting a protective immune response
  • How will the immune response to one virus affect that of another?
  • What are the challenges to funding and commercializing arbovirus vaccines?
Immuno-Oncology
5:20

Strategies for the development of safer and more effective CAR-T therapies

  • General strategies for CAR-T cell control
  • Defining small molecule vs antibody-based targeting – why we use Ab-based targeting.
  • Deep dive into the technicalities of designing these switches to control different targets
  • Universality of the platform and potential for use in solid tumors.
Clinical Trials
5:20

A year of substantial progress: clinical development of TB vaccine candidates

  • A TB vaccine is urgently needed to meet the WHO and UN goals for ending TB
  • Update on status of the overall pipeline of TB vaccine candidates
  • Substantial progress was demonstrated by the results of two efficacy trials of vaccine candidates
  • Implications of the efficacy trial results and takeaways for future candidates and trials
Clinical Trials
5:50

Clinical development of a subunit based congenital CMV vaccine

  • Vaccine development for CMV: High unmet medical need
  • CMV vaccine development at GSK, past and present
  • Critical challenges facing CMV vaccine developers
6:20

Chair closing remarks of day one followed by networking drinks reception

last published: 18/Oct/18 12:55 GMT

 

 

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com